Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer.
Esther P B RodmanMichael J EmchXiaonan HouArchit BajajNicole A PearsonAugust J JohnYamillie OrtizAdam D BassSaloni SinghGustavo BaldassarreScott H KaufmannS John WerohaJohn R HawsePublished in: bioRxiv : the preprint server for biology (2024)
Lestaurtinib is a novel inhibitor of ovarian cancer, including chemotherapy- and PARPi-resistant models, that acts through robust inhibition of the JAK/STAT pathway and synergizes with standard-of-care agents at clinically relevant concentrations.